ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Knight Therapeutics Inc

Knight Therapeutics Inc (GUD)

5.55
0.07
( 1.28% )
Actualizado: 13:37:50

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
5.55
Postura de Compra
5.55
Postura de Venta
5.56
Volume Operado de la Acción
53,301
5.50 Rango del Día 5.55
5.09 Rango de 52 semanas 6.23
Capitalización de Mercado [m]
Precio Anterior
5.48
Precio de Apertura
5.50
Última hora de negociación
13:37:50
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
122,135
Acciones en circulación
101,170,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-33.29
Beneficio por acción (BPA)
-0.17
turnover
331.1M
Beneficio neto
-16.84M

Acerca de Knight Therapeutics Inc

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Montreal, Quebec, Can
Fundado
-
Knight Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker GUD. The last closing price for Knight Therapeutics was $5.48. Over the last year, Knight Therapeutics shares have traded in a share price range of $ 5.09 to $ 6.23.

Knight Therapeutics currently has 101,170,000 shares in issue. The market capitalisation of Knight Therapeutics is $554.41 million. Knight Therapeutics has a price to earnings ratio (PE ratio) of -33.29.

GUD Últimas noticias

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug...

Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico

MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate...

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has...

Knight Therapeutics Reports Third Quarter 2024

MONTREAL, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...

Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call

MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024...

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico

MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate...

Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies

MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine’s...

Knight Therapeutics Reports Second Quarter 2024

MONTREAL, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan- American (ex-US) specialty pharmaceutical company, today reported...

Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call

MONTREAL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2024...

Knight Announces Normal Course Issuer Bid

MONTREAL, July 11, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "),  a leading pan-American (ex-US) specialty pharmaceutical company, announced today...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.234.323308270685.325.555.25660525.36833391CS
40.397.558139534885.165.555.15596945.35957844CS
120.050.9090909090915.55.825.091221355.28102852CS
26-0.27-4.639175257735.826.235.09908255.4732773CS
52-0.16-2.802101576185.716.235.09782155.53410411CS
1560.142.587800369695.416.234.281057905.28472782CS
260-2.47-30.79800498758.028.084.282028985.66939341CS

GUD - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Knight Therapeutics?
El precio actual de las acciones de Knight Therapeutics es $ 5.55
¿Cuántas acciones de Knight Therapeutics están en circulación?
Knight Therapeutics tiene 101,170,000 acciones en circulación
¿Cuál es la capitalización de mercado de Knight Therapeutics?
La capitalización de mercado de Knight Therapeutics es CAD 554.41M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Knight Therapeutics?
Knight Therapeutics ha negociado en un rango de $ 5.09 a $ 6.23 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Knight Therapeutics?
El ratio precio/beneficio de Knight Therapeutics es -33.29
¿Cuál es el ratio de efectivo a ventas de Knight Therapeutics?
El ratio de efectivo a ventas de Knight Therapeutics es 1.69
¿Cuál es la moneda de reporte de Knight Therapeutics?
Knight Therapeutics presenta sus resultados financieros en CAD
¿Cuál es el último ingresos anual de Knight Therapeutics?
El último ingresos anual de Knight Therapeutics es CAD 331.1M
¿Cuál es el último beneficio anual de Knight Therapeutics?
El último beneficio anual de Knight Therapeutics es CAD -16.84M
¿Cuál es la dirección registrada de Knight Therapeutics?
La dirección registrada de Knight Therapeutics es 3400 DE MAISONNEUVE W, SUITE 1055, MONTREAL, QUEBEC, H3Z 3B8
¿Cuál es la dirección del sitio web de Knight Therapeutics?
La dirección del sitio web de Knight Therapeutics es www.gudknight.com
¿En qué sector industrial opera Knight Therapeutics?
Knight Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
OPTOptiva Inc
$ 6.77
(50.44%)
1.41k
SCYScandium International Mining Corp
$ 0.025
(25.00%)
12.05k
DIAMStar Diamond Corporation
$ 0.03
(20.00%)
980.37k
CNTCentury Global Commodities Corporation
$ 0.03
(20.00%)
176k
IVQ.UInvesque Inc
US$ 0.085
(13.33%)
80k
WLLWWillow Biosciences Inc
$ 0.04
(-50.00%)
459.07k
FLNTFlint Corporation
$ 0.025
(-16.67%)
187.68k
AVLAvalon Advanced Materials Inc
$ 0.03
(-14.29%)
271.6k
GVCGlacier Media Inc
$ 0.155
(-11.43%)
11k
NUMINuminus Wellness Inc
$ 0.04
(-11.11%)
189.14k
WNDRWonderFi Technologies Inc
$ 0.375
(5.63%)
9.42M
CNQCanadian Natural Resources Ltd
$ 46.63
(3.60%)
3.63M
PRYMPrime Mining Corp
$ 1.61
(-1.23%)
3.31M
CXBCalibre Mining Corp
$ 2.35
(3.07%)
2.66M
RYRoyal Bank of Canada
$ 173.68
(-0.34%)
2.21M

GUD Discussion

Ver más
sumotrader sumotrader 9 años hace
Loaded 1600 more shares today. GUD is about to take off.
👍️0
CommonCents4Dollars CommonCents4Dollars 10 años hace
This must be some sort of record,.. " the Company reported revenues of $109,608 and net income of $124,981,439."

http://www.gud-knight.com/en/knight-reports-fourth-quarter-and-year-ended-december-31-2014-results
👍️0
CommonCents4Dollars CommonCents4Dollars 10 años hace
Knight Therapeutics GUD.TO : Mackie Research starts with buy rating; target price of C$12

http://www.investorvillage.com/groups.asp?mb=6781&mn=83648&pt=msg&mid=14732670
👍️0
OneStepAhead OneStepAhead 10 años hace
On a tear
👍️0
CommonCents4Dollars CommonCents4Dollars 10 años hace
GOD is GUD. :)
👍️0
CommonCents4Dollars CommonCents4Dollars 10 años hace
KHTRF is the OTC Ticker for Americans
or
GUD on the TSX for Canadians


LONG on this one.
👍️0
CommonCents4Dollars CommonCents4Dollars 10 años hace
GUD is flying along nicely,.. Paladin II is in GUD hands, Goodman building another BEAST!
👍️0
OneStepAhead OneStepAhead 10 años hace
GUD Knight Therapeutics

Knight Therapeutics Inc. ("Knight" or the "Company") (TSX:GUD) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by GMP Securities L.P. and including Cormark Securities Inc., National Bank Financial Inc., Laurentian Bank Securities Inc., Bloom Burton & Co., Clarus Securities Inc., Mackie Research Capital Corporation and TD Securities Inc. (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase 11,111,120 common shares of the Company (the "Common Shares") at a price of $6.75 per Common Share for gross proceeds to Knight of $75,000,060 (the "Offering"). In addition, the Underwriters will have the option, exercisable for a period of 30 days after the closing date, to acquire up to an aggregate of 1,666,668 additional Common Shares ($11,250,009) at the offering price to cover over-allotments, if any (the "Over-Allotment Option"). If the Over-Allotment Option is exercised in full, the total gross proceeds of the Offering shall be $86,250,069.

http://www.marketwired.com/press-release/knight-therapeutics-enters-into-agreement-75-million-bought-deal-common-shares-tsx-gud-1973898.htm
👍️0
OneStepAhead OneStepAhead 10 años hace
GUD Knight Therapeutics

After selling off his specialty pharmaceutical company Paladin Labs Inc. in a deal worth $3-billion, Montreal entrepreneur Jonathan Goodman is starting from scratch with a new drug distribution venture.

http://www.theglobeandmail.com/globe-investor/investment-ideas/a-fresh-stock-with-a-veteran-face/article17189152/
👍️0
Greedy G Greedy G 10 años hace
TNEN:

http://stockcharts.com/h-sc/ui?s=TNEN&p=D&b=5&g=0&id=p74917584188
👍️0

Su Consulta Reciente

Delayed Upgrade Clock